On August 6, the FDA granted accelerated approval to dordaviprone, a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

For more information, read the FDA announcement and the Jazz Pharmaceuticals press release.

Posted on 8/8/2025